Insulin, adipokines and psoriatic arthritis. Review
Clinical Endocrinology and Endocrine Surgery · 30.06.2026 · (2) · 70-83
DOI: 10.30978/cees-2026-2-70 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endocrinology and Endocrine Surgery, online erschienen am 30.06.2026. Verfasst von V. E. Kondratiuk und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-ND 4.0).
Abstract (Originalsprache)
Obesity and metabolic syndrome (MS) are common immune-mediated comorbidities in psoriatic arthritis (PsA) that significantly aggravate and alter the clinical course of the disease. Considering adipose tissue as an active endocrine organ allows for a new perspective on low-grade systemic meta-inflammation, which underlies both metabolic disorders and chronic auto-inflammation of the musculoskeletal system. Objective — to analyze the role of adipose tissue and carbohydrate metabolism disorders in the pathogenesis of PsA, as well as to identify new pharmacological approaches to the treatment of PsA. IR should be considered a fundamental endocrine-metabolic disorder that, via hyperinsulinemia, exerts a direct anabolic effect on keratinocyte proliferation and osteogenic cell differentiation, thereby stimulating osteoproliferation and enthesopathies. The profile of adipokines (primarily adiponectin, leptin, and resistin) secreted by dysfunctional adipocytes acts as a direct mediator of inflammation. The shift of adipose tissue toward a pro-inflammatory M1 macrophage phenotype leads to a critical reduction in protective adiponectin and overproduction of leptin and resistin. Through the activation of nuclear factor-kappa B (NF-kappa B) and c-Jun N-terminal kinase (JNK) signaling pathways, these adipokines potentiate the pro-inflammatory immune axes of interleukins (IL)-23/IL-17 and tumor necrosis factor-a (TNF- a), which jointly influence the development and progression of articular syndrome in PsA. Concurrently, excess resist in stimulates directly osteoclastogenesis and cartilage degradation, whereas the administration of glucagon-like peptide-1 (GLP‑1) receptor agonists, metformin, and sodium-glucose cotransporter 2 (SGLT2) inhibitors allows for the suppression of these destructive processes by reducing systemic oxidative stress and pro-inflammatory gene expression. Conclusions. The analysis of molecular interactions not only improves the understanding of the synergism between IR and adipokine imbalance but also identifies novel therapeutic targets. The prescription of metabolic agents (metformin, SGLT2 inhibitors, GLP-1 receptor agonists) that enhance insulin sensitivity and lower systemic cytokine levels represents a promising therapeutic approach for the simultaneous management of both metabolic and articular manifestations of psoriatic disease.
Zitieren
APA
Kondratiuk, V. E., & Stakhova, A. P. (2026). Insulin, adipokines and psoriatic arthritis. Review. Clinical Endocrinology and Endocrine Surgery, 70-83. https://doi.org/10.30978/cees-2026-2-70
Vancouver
Kondratiuk VE, Stakhova AP. Insulin, adipokines and psoriatic arthritis. Review. Clinical Endocrinology and Endocrine Surgery. 2026:70-83. doi:10.30978/cees-2026-2-70
BibTeX
@article{Kondratiuk2026,
author = {Kondratiuk, V. E. and Stakhova, A. P.},
title = {Insulin, adipokines and psoriatic arthritis. Review},
journal = {Clinical Endocrinology and Endocrine Surgery},
year = {2026},
number = {2},
pages = {70--83},
doi = {10.30978/cees-2026-2-70}
}
EUVIMED